Inspirata AI Strengthens Cancer Registry Platform with AI
TAMPA, Fla., July 16, 2026 Inspirata AI has officially unveiled its new corporate identity, transitioning from Inspirata to Inspirata...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
TAMPA, Fla., July 16, 2026 Inspirata AI has officially unveiled its new corporate identity, transitioning from Inspirata to Inspirata...
Boston, Massachusetts, United States | April 30, 2026 A new study led by researchers at Harvard Medical School and...
September 17, 2025 — Columbia, S.C., ALLT.AI has introduced a new generation of large language models (LLMs) that draw...
